Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT)

@inproceedings{PardoLozano2012ClinicalPO,
  title={Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT)},
  author={Ricardo Pardo-Lozano and Mag{\'i} Farr{\'e} and Samanta Yubero-Lahoz and Brian O’Math{\'u}na and Marta Torrens and Cristina Mustata and C P{\'e}rez-Ma{\~n}{\'a} and Klaus Langohr and Elisabet Cuy{\'a}s and Marcel·l{\'i} Carb{\'o} and Rafael de la Torre},
  booktitle={PloS one},
  year={2012}
}
UNLABELLED The synthetic psychostimulant MDMA (± 3,4-methylenedioxymethamphetamine, ecstasy) acts as an indirect serotonin, dopamine, and norepinephrine agonist and as a mechanism-based inhibitor of the cytochrome P-450 2D6 (CYP2D6). It has been suggested that women are more sensitive to MDMA effects than men but no clinical experimental studies have satisfactorily evaluated the factors contributing to such observations. There are no studies evaluating the influence of genetic polymorphism on… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 10 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 53 references

The influence of genetic and environmental factors among MDMA users in cognitive performance

  • E Cuyàs, A Verdejo-Garcı́a, AB Fagundo, O Khymenets, J Rodrı́guez
  • PLoS One
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…